Загрузка...
Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
INTRODUCTION: The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic cast...
Сохранить в:
| Опубликовано в: : | IJU Case Rep |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292117/ https://ncbi.nlm.nih.gov/pubmed/32743362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/iju5.12026 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|